Arch Biopartners, Inc. ARCH
TSXV · Canada · Health Technology
CAD 0.8300-0.06 (-6.74%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced that the Company will expand the study into the United States following interest from clinicians at five leading i
Arch Biopartners (ARCH.V) will expand its Phase II trial of LSALT peptide into the US, with five ins
TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”) into the United States, following interest from clinicians at five leading U.S. institutions. The planned U.S. expansion builds on progress at the four Canadian clinical sites currently participating in the trial and patient data collected f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.